DNTHDianthus Therapeutics, Inc.

DNTH Stock Price, Valuation & Chart | Dianthus Therapeutics, Inc.

Compare

$106.24-0.38 (-0.36%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology DNTH intrinsic value DNTH calculated fair value vs price

Overview Financials Dividends Ratios

DNTH Historical price chart

DNTH Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization5.94B

PE Ratio-25.6

EPS-4.15

Trading Volume565.13K

Today's High/Low110.44/103.23

Dividend Yield0.00

52 Week High/Low117.88/23.66

Shares Outstanding55.93M

DNTH Financial Statement

DNTH Analyst ratings

DNTH Analysis & performance metrics

DNTH Company profile

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe…

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating…

DNTH Management team

Name

Position

Edward G. Carr

Chief Accounting Officer

Adam M. Veness Esq.

Senior Vice President, General Counsel & Secretary

Scott Nogi M.B.A.

Head of Business Operations

Ryan SavitzCFO

Chief Financial Officer & Chief Business Officer

Kristina Maximenko

Chief People Officer

Rashieda Gluck

Head of Clinical Development Operations

Judson Taylor

Senior Vice President & Head of Technical Operations

Marino Garcia M.B.A.CEO

President, Chief Executive Officer & Director

Name

Position

Edward G. Carr

Chief Accounting Officer

Adam M. Veness Esq.

Senior Vice President, General Counsel & Secretary

Scott Nogi M.B.A.

Head of Business Operations

Ryan SavitzCFO

Chief Financial Officer & Chief Business Officer

Kristina Maximenko

Chief People Officer

Rashieda Gluck

Head of Clinical Development Operations

Judson Taylor

Senior Vice President & Head of Technical Operations

Marino Garcia M.B.A.CEO

President, Chief Executive Officer & Director

Management Team

Edward G. Carr

Chief Accounting Officer

Adam M. Veness Esq.

Senior Vice President, General Counsel & Secretary

Scott Nogi M.B.A.

Head of Business Operations

Ryan SavitzCFO

Chief Financial Officer & Chief Business Officer

Kristina Maximenko

Chief People Officer

Rashieda Gluck

Head of Clinical Development Operations

Judson Taylor

Senior Vice President & Head of Technical Operations

Marino Garcia M.B.A.CEO

President, Chief Executive Officer & Director

Management

Edward G. Carr

Chief Accounting Officer

Adam M. Veness Esq.

Senior Vice President, General Counsel & Secretary

Scott Nogi M.B.A.

Head of Business Operations

Ryan SavitzCFO

Chief Financial Officer & Chief Business Officer

Kristina Maximenko

Chief People Officer

Rashieda Gluck

Head of Clinical Development Operations

Judson Taylor

Senior Vice President & Head of Technical Operations

Marino Garcia M.B.A.CEO

President, Chief Executive Officer & Director

Total 8 executives

DNTH Frequently asked questions

What is Dianthus Therapeutics, Inc. (DNTH) Stock Price?

Current stock price of Dianthus Therapeutics, Inc. (DNTH) stock is $106.24. The stock price is -0.36% lower in the session. The intraday range can be seen from this page. Volume of Dianthus Therapeutics, Inc. (DNTH) stock is 565.13K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Dianthus Therapeutics, Inc. (DNTH) stock price going up or down today?

The stock price of Dianthus Therapeutics, Inc. (DNTH) can change with earnings, company news, and overall market sentiment. Dianthus Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Dianthus Therapeutics, Inc. stock expensive at its current price?

Whether Dianthus Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for DNTH on this page is -25.60. EPS on this page is -4.15. Compare those figures with peers and growth expectations before deciding if the current Dianthus Therapeutics, Inc. price is justified.

How has the stock price of Dianthus Therapeutics, Inc. (DNTH) performed historically?

Historical performance for Dianthus Therapeutics, Inc. (DNTH) is shown on the price chart on this page. Review multi-period moves alongside volume to see how DNTH reacted to past earnings and market events.

Should I buy Dianthus Therapeutics, Inc. (DNTH) stock, at this price?

Buying Dianthus Therapeutics, Inc. (DNTH) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.